CVS Health outlined its efforts to decrease prior authorizations, reduce hospital readmissions and emergency room visits and ...
AbbVie Inc. (NYSE:ABBV) is included among the 15 Best S&P 500 Dividend Stocks to Buy in 2026. On January 20, Berenberg raised ...
The Dividend Aristocrats are a group of stocks in the S&P 500 Index with over 25 consecutive years of dividend increases. These high-quality businesses have managed recessions and various crises, ...
As Sandoz looks to address the “biosimilar void” created by the scores of lucrative drugs going off patent in the next decade ...
The S&P 500 touched 7,000 as tech stocks rallied on AI optimism, with investors focused on earnings, profitability and ...
AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers ...
Using same proprietary, patented technology, VIVI Med extends the product portfolio beyond injectable pens, opening access to broader patient populations, premium biologics, and institutional ...
Johnson & Johnson (NYSE:JNJ) Q4 2025 Earnings Call Transcript January 21, 2026 Johnson & Johnson reports earnings inline with ...
These stocks offer impressive long-term upside with downside protection.
Extracting therapeutic antibodies from biological systems requires stringent purification processes. To reduce costs and accelerate development, novel strategies are essential ...
As of Friday, January 23, Coherus Oncology, Inc.’s CHRS share price has surged by 21.70%, which has investors questioning if ...
CVS Health cuts prior authorizations, speeding approvals and expanding biosimilar use to reduce costs and improve patient access.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results